⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7205826 | 0.74 | — | — | |
| SCHEMBL3986767 | 0.72 | — | — | |
| SCHEMBL1710031 | 0.72 | — | — | |
| SCHEMBL12744460 | 0.72 | — | — | |
| Nitrous Acid SCHEMBL17395924 | 0.68 | — | — | |
| SCHEMBL5616656 | 0.67 | — | — | |
| SCHEMBL724052 | 0.65 | — | — | |
| SCHEMBL8848567 | 0.65 | — | — | |
| SCHEMBL5849578 | 0.65 | — | — | |
| SCHEMBL325170 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952573-B2 | RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20240092819-A1 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | SANOFI SA (FR) | 2024-03-21 | — | — | US | disclosed |
| US-11932854-B2 | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-11897911-B2 | Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same | SANOFI (FR) | 2024-02-13 | — | — | US | disclosed |
| US-20230348904-A1 | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS | BANK OF AMERICA, N.A. | 2023-11-02 | — | — | US | disclosed |
| EP-4232455-A2 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | Sanofi (FR) | 2023-08-30 | — | — | EP | disclosed |
| US-20230144623-A1 | SYSTEMIC DELIVERY OF MYOSTATIN SHORT INTERFERING NUCLEIC ACIDS (SINA) CONJUGATED TO A LIPOPHILIC MOIETY | SIRNA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230030119-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | SIRNA THERAPEUTICS, INC | 2023-02-02 | — | — | US | disclosed |
| US-11530407-B2 | Short interfering nucleic acid (siNA) compositions | SIRNA THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11529428-B2 | Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety | BANK OF AMERICA, N.A. | 2022-12-20 | — | — | US | disclosed |
| US-7615618-B2 | Oligonucleotides comprising a non-phosphate backbone linkage | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615618-B2 | Oligonucleotides comprising a non-phosphate backbone linkage | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| WO-2008116267-A1 | THERAPEUTIC TARGETS AND MOLECULES | CRC FOR ASTHMA AND AIRWAYS LTD (AU) | 2008-10-02 | — | — | WO | disclosed |
| EP-1789553-A2 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | Alnylam Pharmaceuticals Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1789553-A2 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | Alnylam Pharmaceuticals Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006088490-A3 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | ALNYLAM PHARMACEUTICALS INC (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20060287260-A1 | Ribonucleoside substituted with a phosphonamidite group at the 3'-position; the phosphonamidite may be an alkyl phosphonamidite; can be used to prepare oligonucleotides used in gene therapy; improved serum solubility, cellular distribution and uptake, and stability in vivo | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-12-21 | — | — | US | disclosed |
| US-20060287260-A1 | Ribonucleoside substituted with a phosphonamidite group at the 3'-position; the phosphonamidite may be an alkyl phosphonamidite; can be used to prepare oligonucleotides used in gene therapy; improved serum solubility, cellular distribution and uptake, and stability in vivo | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-12-21 | — | — | US | disclosed |
| WO-2006088490-A2 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| WO-2006088490-A2 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | WO | disclosed |